SKLB 1028 - CSPC Ouyi Pharmaceutical

Drug Profile

SKLB 1028 - CSPC Ouyi Pharmaceutical

Alternative Names: SKLB-1028

Latest Information Update: 11 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSPC Ouyi Pharmaceutical
  • Class
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Epidermal growth factor inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 01 May 2016 Phase-I clinical trials in Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in China (PO) (NCT02859948)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top